Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Leases: 2019-2024

Historic Current Leases for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $2.2 million.

  • Fulcrum Therapeutics' Current Leases rose 10.03% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 10.03%. This contributed to the annual value of $2.2 million for FY2024, which is 0.27% down from last year.
  • As of FY2024, Fulcrum Therapeutics' Current Leases stood at $2.2 million, which was down 0.27% from $2.2 million recorded in FY2023.
  • In the past 5 years, Fulcrum Therapeutics' Current Leases registered a high of $2.6 million during FY2022, and its lowest value of $469,000 during FY2020.
  • Its 3-year average for Current Leases is $2.3 million, with a median of $2.2 million in 2023.
  • Its Current Leases has fluctuated over the past 5 years, first spiked by 454.80% in 2022, then decreased by 15.76% in 2023.
  • Yearly analysis of 5 years shows Fulcrum Therapeutics' Current Leases stood at $469,000 in 2020, then remained steady at $469,000 in 2021, then skyrocketed by 454.80% to $2.6 million in 2022, then fell by 15.76% to $2.2 million in 2023, then fell by 0.27% to $2.2 million in 2024.